Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol KAT2B contributors: shn/npt/pgu - updated : 04-03-2016
HGNC name K(lysine) acetyltransferase 2B
HGNC id 8638
RNA
TRANSCRIPTS type messenger
identificationnb exonstypebpproduct
ProteinkDaAAspecific expressionYearPubmed
18 - 4824 - 832 - 2012 23001180
EXPRESSION
Type ubiquitous
   expressed in (based on citations)
organ(s)
SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
Cardiovascularheart   highly
Digestiveliver   lowly
Endocrinepancreas   predominantly
Nervousbrain   predominantly
Reproductivefemale systemplacenta  moderately
Respiratorylung   lowly
Urinarykidney   lowly
tissue
SystemTissueTissue level 1Tissue level 2LevelPubmedSpeciesStageRna symbol
Muscular   highly
cell lineage
cell lines
fluid/secretion
at STAGE
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
  • one acetyltransferase domain
  • one bromodomain
  • mono polymer heteromer , dimer
    HOMOLOGY
    interspecies homolog to GCN5, yeast
    ortholog to kat2b, Danio rerio
    ortholog to Kat2b, mus musculus
    ortholog to KAT2B, Pan troglodytes
    Homologene
    FAMILY
  • GCN5 family
  • CATEGORY enzyme , regulatory , transcription factor
    SUBCELLULAR LOCALIZATION     intracellular
    intracellular,nucleus,nucleoplasm
    intracellular,nucleus,chromatin/chromosome,kinetochore
    basic FUNCTION
  • has histone acetyl transferase activity with core histones and nucleosome core particles
  • plays a direct role in transcriptional regulation
  • possessing intrinsic histone acetylase activity with core histones and nucleosome core particles
  • competing with an adenoviral oncoprotein E1A
  • inhibiting cell-cycle
  • acetylation of Myod
  • regulator with CREBBP of involucrin expression in stratified squamous epithelial cells
  • acting as a coactivator of ATF4 and is involved in the enhancement of DDIT3 transcription following amino acid starvation
  • playing a role in regulation of muscle contraction
  • probably takes part in transcriptional regulations of various BCR signalling- and apoptosis-related genes, especially including DFFA and BIRC2 genes
  • may control transcription both positively and negatively at the level of chromatin modification and via direct interactions with the TATA-binding protein (TBP)
  • might be the target tumor suppressive gene responsible for the 3p24 deletion event in esophageal squamous cell carcinoma
  • inhibits the activity of cyclin/CDK2 complexes
  • acts downstream of PTH signaling as a transcriptional coactivator that is required for PTH stimulation of MMP13 transcription
  • required for stress-responsive histone 3 acetylation at the CDKN1A promoter, TP53-directed transcription of CDKN1A and the resultant growth arrest
  • functions as a transcriptional coactivator, which may facilitate the formation of memory for fear extinction by interfering with reconsolidation of the original memory trace
  • function in mitotic chromosome congression by regulating spindle plus-end dynamics
  • important regulator for promoting osteoblast differentiation via acetylation modification of RUNX2
  • CELLULAR PROCESS cell cycle, progression
    cell life, differentiation
    nucleotide, chromatin organization, remodeling
    nucleotide, transcription, regulation
    PHYSIOLOGICAL PROCESS development
    text
  • muscle differentiation
  • calcium-induced keratinocyte differentiation
  • PATHWAY
    metabolism
    signaling hormonal
    a component
  • component of the mammalian STAGA (SUPT3H-TAF9-ADA-PCAF acetyltransferase) a chromatin-acetylating transcription coactivator that interacts with pre-mRNA splicing and DNA damage-binding factors
  • with BCR signalling are essential for apoptotic cell death
  • part of a GCN5/PCAF Complex (ATAC) distinct from STAGA
  • both STAGA and ATAC acetylate specifically nucleosomal histone H3
  • INTERACTION
    DNA
    RNA
    small molecule
    protein
  • acetylating SCL (TAL1)
  • CBP and p300
  • activating HDAC13
  • binding to TP73(coactivator for TP73-mediated transactivation
  • MYOD1
  • interaction partner of ATF4 in leucine-starved cells
  • PTEN
  • directly interacts with CDK2 (this interaction is mainly produced during S and G(2)/M phases of the cell cycle)
  • KLF8 activation domain located between AAs 101-260 where the well-conserved Q118 and Q248 are essential for recruiting EP300 and KAT2B to activate target gene transcription
  • ESRRA interacts with and is acetylated by EP300 coactivator associated factor (KAT2B)
  • cooperates with EP300 and RUNX2 to mediate PTH activation of MMP13 transcription
  • induces CDKN1B degradation via proteasome
  • critical regulator of TP53-dependent CDKN1A expression in response to multiple TP53-activating stresses
  • selective influence of KAT2B on fear extinction is mediated, in part, by a transient recruitment of the repressive transcription factor ATF4 to the promoter of the immediate early gene EGR2, which competitively inhibits its expression
  • acts as a negative modulator of microtubule stability through acetylation of MAPRE1, a protein that controls the plus ends of microtubules
  • in mitosis, acetylates the mitotic checkpoint protein, BUB1B
  • directly binds to RUNX2 and acetylates RUNX2, leading to an increase in its transcriptional activity
  • EP300 and KAT2B are two TRIM50 acetyltransferases and the balance between ubiquitination and acetylation regulates TRIM50 degradation
  • KAT2B and TADA3 regulate BID processing via PACS2, to modulate the mitochondrial cell death pathway in response to GZMB
  • KAT2A/KAT2B acetylation of PLK4 prevents centrosome amplification
  • cell & other
    REGULATION
    inhibited by
  • DEK
  • repressed by
  • DEK
  • ASSOCIATED DISORDERS
    corresponding disease(s)
    Susceptibility to survival advantage in elderly patients
    Variant & Polymorphism SNP
  • the -2481C allele in the promoter is associated with a significant survival advantage in elderly patients
  • Candidate gene
    Marker
    Therapy target
    SystemTypeDisorderPubmed
    cancer  
    new rationale for therapeutic targeting of KAT2B activity in tumors harboring oncogenic versions of TP53
    ANIMAL & CELL MODELS